Blog

Jill Feldman: Interesting finding for people with EFGR lung cancer that transforms to SCLC

Jill Feldman/X

Oct 15, 2024, 17:29

Jill Feldman: Interesting finding for people with EFGR lung cancer that transforms to SCLC

Jill Feldman shared a post on X by Stephen V Liu adding:

“Very interesting finding for people with EFGR lung cancer that transforms to SCLC! It appears that DLL3 was not present before transformation, but most patients showed DLL3 expression after it.

Currently, there isn’t a good standard treatment, but further studies are needed to understand and determine if treatments targeting DLL3, such as tarlatamab, could be an option for patients after transformation.”

Quoting Stephen V Liu’s post below:

“Retrospective report in European Journal of Cancer on EGFR mutant NSCLC transformed to SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO).”

Read Further.

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR-positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.

Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.